Welcome to our dedicated page for Bone Biologics news (Ticker: BBLG), a resource for investors and traders seeking the latest updates and insights on Bone Biologics stock.
Bone Biologics Corporation (NASDAQ: BBLG, BBLGW) is a biotechnology company developing orthobiologic products for spine fusion markets, with a focus on bone regeneration using NELL-1-based technology. This news page brings together company announcements and disclosures that highlight its scientific, clinical, operational and capital markets activities.
Readers can review updates on Bone Biologics’ lead product candidate NB1, which the company describes as a combination of recombinant human NELL-1 (rhNELL-1) and demineralized bone matrix for use as a bone graft in spinal fusion procedures. News items include descriptions of the company’s first-in-human clinical study in degenerative disc disease, where NB1 is being evaluated for safety and preliminary effectiveness in transforaminal lumbar interbody fusion.
Coverage also includes operational milestones such as extensions of rhNELL-1 shelf life from earlier 12- and 18-month validations to a reported 24-month validated shelf life, as well as formulation improvements intended to support scaled manufacturing. Intellectual property developments, including the filing of a U.S. patent application for compositions of rhNELL-1 polypeptide and uses in treating bone conditions, are documented in press releases.
Investors and observers can find information on public offerings of common stock and warrants, reverse stock split actions, and communications about Nasdaq listing compliance. The company’s participation in investor conferences and stockholder letters discussing clinical progress, manufacturing readiness, and outlook for NB1 are also reflected in the news flow. This page serves as a centralized source for Bone Biologics’ historical news, helping users follow its orthobiologic development program and related corporate events over time.
Bone Biologics Corporation (NASDAQ: BBLG) announced a public offering of 3,777,778 units at $1.35 per unit, raising total gross proceeds of $5.1 million. Each unit includes a share of common stock and various warrants, with exercise prices ranging from $1.35 to $2.16. The offering is expected to close on or about October 11, 2022. An additional 566,666 shares and/or warrants may be offered by underwriters for over-allotments. This offering is registered under Form S-1 and follows SEC approval on October 6, 2022.
Summary not available.
Bone Biologics Corporation (NASDAQ: BBLG), specializing in orthobiologic products for spine fusion, will have its president and CEO, Jeffrey Frelick, present at the 2022 Virtual Growth Conference by Maxim Group LLC from March 28-30, 2022. A pre-recorded presentation will be accessible for 72 hours starting March 28 at 9:00 a.m. ET. Interested individuals can view the presentation via the company's investor relations page or directly on the conference's site.
Bone Biologics focuses on innovative bone regeneration solutions, particularly using the Nell-1 protein for spinal fusion and other applications.
Bone Biologics Corporation (NASDAQ: BBLG) has established a supply agreement with MTF Biologics for demineralized bone matrix (DBM), essential for developing a bone graft substitute product using rhNELL-1. This agreement supports a 30-patient pilot study and a subsequent pivotal study in spine fusion patients. CEO Jeff Frelick emphasized the significance of this milestone in the $3 billion spine fusion market, aiming to create a product with unique benefits compared to existing options.
Bone Biologics Corporation (NASDAQ: BBLG) has announced that its CEO, Jeffrey Frelick, will present at the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022. A pre-recorded presentation will be available starting January 10 at 7:00 a.m. ET. Interested viewers can access the presentation via the company's investor relations website.
The company specializes in developing orthobiologic products aimed at spinal fusion, focusing on bone regeneration through its innovative research on the Nell-1 protein.
Bone Biologics Corp. (NASDAQ: BBLG) has successfully closed a public offering of 1,510,455 units at $5.25 each, raising approximately $7.9 million. Each unit includes one share of common stock and a warrant, which is exercisable at $6.30 per share for five years. The offering followed a 1-for-2.5 reverse stock split and began trading on Nasdaq on October 13, 2021. The underwriters have a 45-day option to purchase additional securities. This offering is registered under Form S-1 with the SEC, indicating the company’s ongoing efforts in regenerative medicine for bone.
WallachBeth Capital announced the successful completion of an underwritten public offering for Bone Biologics (NASDAQ: BBLG), raising $7.9 million through the sale of 1,510,455 units at an offering price of $5.25 per unit. Each unit includes one share of common stock and one warrant, exercisable at $6.30 per share. The company also granted underwriters a 45-day option to purchase additional shares to cover over-allotments. Following a reverse stock split on October 12, 2021, BBLG and its warrants began trading on Nasdaq on October 13, 2021.
WallachBeth Capital LLC has priced an underwritten public offering of 1,510,455 units of Bone Biologics (NASDAQ: BBLG) at $5.25 per unit, totaling gross proceeds of $7.9 million before expenses. Each unit consists of one share of common stock and one warrant, exercisable at $6.30 for five years. The offering includes a 45-day option for underwriters to purchase additional shares and warrants. A reverse stock split at a 1-for-2.5 ratio was also implemented. Trading for BBLG and BBLGW began on October 13, 2021, with the offering closing expected around October 15, 2021.
Bone Biologics Corp. (NASDAQ: BBLG) announced the pricing of its public offering of 1,510,455 units at $5.25 each, raising gross proceeds of approximately $7.9 million. Each unit comprises one share of common stock and one warrant to buy a share at $6.30, expiring in five years. The offering, effective October 15, 2021, follows a 1-for-2.5 reverse stock split executed on October 12, 2021. Underwriters may purchase an additional 226,568 shares for overallotments. Trading began on October 13, 2021. WallachBeth Capital is the book-running manager.